Advanced Nurse Hit with DEA Decision on Drug Authority
Published Date: 10/30/2025
Notice
Summary
Tracy Amerson-Rivers, an advanced practice nurse from Texas, had her DEA registration suspended and then revoked because she prescribed controlled drugs without the required doctor’s approval and was accused of fraud. This means she can no longer legally prescribe these medications, protecting public safety. The revocation is final, even though her registration expired in June 2025, and it sends a clear message about following the rules.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
DEA Registration Revoked — No Prescribing
The DEA revoked Tracy Amerson-Rivers' Certificate of Registration No. MA5242792, effective December 1, 2025, so she can no longer legally prescribe controlled substances. The Agency found she issued six controlled-substance prescriptions without prescriptive authority between March 5, 2023 and April 20, 2023 and that she obtained alprazolam by fraud on March 15, 2023.
Renewal and New Registrations Denied
The Order also denies any pending applications by Tracy Amerson-Rivers to renew or modify registration No. MA5242792 and denies any other pending application of hers for additional registration in Texas. The record shows her DEA registration had expired on June 30, 2025, and the denial accompanies the revocation effective December 1, 2025.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-19708, Pharmacy Place, Llc; Decision and Order
Pharmacy Place, LLC in Houston had its DEA registration suspended and is facing revocation because it filled many controlled substance prescriptions improperly and broke recordkeeping rules. This decision protects public health by stopping unsafe pharmacy practices. Pharmacy Place must fix these issues or lose its ability to handle controlled drugs, affecting their business and customers starting now.
Next: 2025-19710, Antony Vanbang, M.D.; Decision and Order
Dr. Antony Vanbang from Denver lost his medical license in Colorado and didn’t ask for a hearing to fight it. Because of this, the DEA is officially taking away his registration to handle controlled substances, meaning he can no longer prescribe or manage these drugs. This decision is final and affects Dr. Vanbang immediately, stopping him from legally working with controlled medicines.